Global AI in Diagnostics Market to Register Stunning Growth at a CAGR of ~22% by 2032 | DelveInsight

The increasing incidence of infectious and chronic illnesses is boosting the need for early and precise diagnosis, with AI playing a crucial role by improving detection and enabling quicker clinical decisions. At the same time, the widespread adoption of digital health and imaging technologies creates a solid base for integrating AI into current healthcare systems, enhancing both efficiency and accuracy. Furthermore, ongoing product innovation by major global players, driven by progress in machine learning and growing regulatory backing, is accelerating the availability of AI-based diagnostic solutions.

New York, USA, May 21, 2025 (GLOBE NEWSWIRE) — Global AI in Diagnostics Market to Register Stunning Growth at a CAGR of ~22% by 2032 | DelveInsight

The increasing incidence of infectious and chronic illnesses is boosting the need for early and precise diagnosis, with AI playing a crucial role by improving detection and enabling quicker clinical decisions. At the same time, the widespread adoption of digital health and imaging technologies creates a solid base for integrating AI into current healthcare systems, enhancing both efficiency and accuracy. Furthermore, ongoing product innovation by major global players, driven by progress in machine learning and growing regulatory backing, is accelerating the availability of AI-based diagnostic solutions.

DelveInsight’s AI in Diagnostics Market Insights report provides the current and forecast market analysis, individual leading AI in diagnostics companies’ market shares, challenges, AI in diagnostics market drivers, barriers, trends, and key market AI in diagnostics companies in the market.

Key Takeaways from the AI in Diagnostics Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global AI in diagnostics market during the forecast period. 
• In the component segment of the AI in diagnostics market, the software category captured a significant revenue share in 2024.
• Notable AI in diagnostics companies such as Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and several others are currently operating in the AI in diagnostics market.
• In September 2024, Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, introduced the latest advancements in its innovative product platform, Ibex-AI. These new features, developed in collaboration with expert pathologists worldwide who actively use the platform in routine clinical practice, highlight Ibex’s ongoing commitment to creating cutting-edge diagnostic tools tailored to the needs of healthcare professionals on the frontlines of patient care.
• In October 2023, Lucida Medical Ltd announced that it received Class IIb CE certification for its AI-powered prostate cancer detection software, Prostate IntelligenceTM (PiTM). Leveraging advanced AI technology, PiTM analyzes MRI scans and is seamlessly integrated into the radiologist’s workflow.
• In March 2023, Qritive launched its latest AI-driven innovation, QAi Prostate, designed specifically for prostate cancer diagnosis. Utilizing cutting-edge machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies with high precision.

To read more about the latest highlights related to the AI in diagnostics market, get a snapshot of the key highlights entailed in the Global AI in Diagnostics Market Report

AI in Diagnostics Overview

Artificial Intelligence (AI) is revolutionizing diagnostics by enabling faster, more accurate detection of diseases through advanced data analysis and pattern recognition. AI-powered systems can analyze medical images such as X-rays, MRIs, and CT scans with high precision, often matching or exceeding the performance of human radiologists in identifying abnormalities like tumors, fractures, or infections. By processing vast amounts of data from electronic health records, lab results, and genomics, AI algorithms can also uncover hidden correlations, assist in early disease prediction, and support personalized treatment plans.

Moreover, AI is streamlining workflows in diagnostic laboratories and reducing the burden on healthcare professionals. For instance, AI-driven tools can automate routine tasks such as blood sample analysis or pathology slide interpretation, allowing clinicians to focus on complex cases. In resource-constrained settings, AI has the potential to bridge the gap in healthcare access by providing decision support to less experienced practitioners. As AI continues to evolve, integrating real-time data and improving interpretability, it holds the promise of significantly enhancing diagnostic accuracy, speed, and overall patient outcomes.

AI in Diagnostics Market Insights

North America is expected to dominate the overall Artificial Intelligence (AI) in Diagnostics market over the forecast period, driven by advanced healthcare infrastructure, significant investments in AI technologies, and widespread adoption of digital health solutions. The United States, in particular, leads the region due to its early adoption of cutting-edge technologies, strong presence of leading AI and healthcare companies, and supportive regulatory frameworks. 

The growing demand for early and accurate diagnosis, especially for chronic and complex diseases such as cancer and cardiovascular conditions, has propelled the integration of AI into diagnostic tools and platforms. Major healthcare institutions in the region are increasingly leveraging AI algorithms for imaging analysis, pathology, and predictive diagnostics, further accelerating market growth.

Moreover, robust government initiatives and funding programs supporting AI research in healthcare continue to fuel innovation and development. Strategic collaborations between technology firms and medical institutions are resulting in AI solutions with improved accuracy and efficiency, contributing to enhanced patient outcomes. 

The presence of a tech-savvy population, favorable reimbursement policies for AI-enabled diagnostic procedures, and a well-established ecosystem of data-driven healthcare systems also contribute to North America’s leading position in this domain. As AI technologies mature and gain greater clinical acceptance, the region is expected to remain at the forefront of global advancements in AI-driven diagnostics.

To know more about why North America is leading the market growth in the AI in diagnostics market, get a snapshot of the AI in Diagnostics Market Outlook 

AI in Diagnostics Market Dynamics

The AI in diagnostics market has seen significant growth due to technological advancements in machine learning (ML) and artificial intelligence (AI), allowing for the automation and enhancement of diagnostic processes. AI-powered diagnostic tools are revolutionizing areas such as imaging, pathology, and molecular diagnostics, enabling faster, more accurate results with reduced human error. This has become especially crucial in areas like cancer detection, where early identification can significantly impact treatment outcomes. AI algorithms, capable of analyzing vast datasets, can detect patterns and abnormalities in medical imaging that may be missed by the human eye, leading to earlier intervention.

The market dynamics are also being influenced by the increasing demand for personalized healthcare. As healthcare systems move towards precision medicine, AI in diagnostics plays a vital role by tailoring diagnostic tests and treatments based on individual genetic profiles. This is particularly significant in oncology, where molecular diagnostics are being enhanced by AI to offer more targeted therapeutic options. With this move toward personalized diagnostics, the role of AI in predicting disease outcomes and treatment responses continues to expand, driving the need for more sophisticated diagnostic tools.

Furthermore, regulatory approvals and integration with healthcare systems are key to AI’s success in diagnostics. Governments and healthcare bodies are gradually developing guidelines for AI in clinical settings, which is boosting investor confidence and enabling more widespread adoption. However, challenges such as data privacy concerns, interoperability issues, and the need for large-scale validation studies still pose barriers to the full-scale integration of AI diagnostics. As a result, partnerships between AI companies and traditional diagnostic firms are becoming more common to combine the strengths of AI technologies with the reliability and credibility of established healthcare systems.

The growing prevalence of chronic diseases and the increasing burden on healthcare systems globally are also driving the adoption of AI in diagnostics. AI can assist in managing large patient populations by streamlining workflows, reducing diagnostic errors, and providing healthcare professionals with better decision-making tools. The market is also seeing the emergence of AI-driven platforms that offer end-to-end diagnostic solutions, from initial patient consultation to final diagnosis, creating a more seamless healthcare experience. As AI technologies continue to mature, the market is expected to experience even greater expansion, making healthcare more accessible, efficient, and accurate.

Get a sneak peek at the AI in diagnostics market dynamics @ AI in Diagnostics Market Dynamic Analysis 

AI in Diagnostics Market Assessment

• AI in Diagnostics Market Segmentation
  • AI in Diagnostics Market Segmentation By Component: Hardware/software, and Services
  • AI in Diagnostics Market Segmentation By Application: Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others
  • AI in Diagnostics Market Segmentation By Technology: Machine Learning, Natural Language Processing, and Others
  • AI in Diagnostics Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Which MedTech key players in the AI in diagnostics market are set to emerge as the trendsetter explore @ AI in Diagnostics Companies 

Table of Contents 

Interested in knowing the AI in diagnostics market by 2032? Click to get a snapshot of the AI in Diagnostics Market Trends

Related Reports

AI in Cancer Diagnostics Market

AI in Cancer Diagnostics Market Insights, Competitive Landscape, and Market Forecast – 2032 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key AI in cancer diagnostics companies, including iCAD, Inc., ibex-ai, Roche Diagnostics, Kheiron Medical Technologies Limited, MVision AI Inc., Siemens Healthineers AG, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., IBM Corporation, Azra AI, ConcertAI, PathAI, Median Technologies, Paige AI Inc., Therapixel, Flatiron, Freenome Holdings Inc., Onc.AI, Sonrai Analytics, among others.

Artificial Intelligence In Clinical Trials Market

Artificial Intelligence In Clinical Trials Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in clinical trials companies, including TEMPUS, NetraMark, ConcertAI, AiCure, Medpace, Inc., ICON plc, Charles River Laboratories, Dassault Systèmes, Oracle, Certara, Cytel Inc., Phesi, DeepHealth, Unlearn.ai, Inc., H1, TrialX, Suvoda LLC, Risklick, Lokavant, Research Solutions, among others.

Artificial Intelligence In Drug Discovery Market

Artificial Intelligence In Drug Discovery Market Insights, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key AI in drug discovery companies, including IBM Corporation, Numedii Inc, Deep Genomics, NVIDIA Corporation, Atomwise Inc, Cloud Pharmaceuticals Inc, Alphabet Inc (DeepMind), Insilico Medicine, BenevolentAI, Exscientia, Cyclia, Valo Health, Owkin Inc, Verge Genomics, BioSymetrics, among others.

Artificial Intelligence in Drug Commercialization Market

Artificial Intelligence in Drug Commercialization Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in drug commercialization companies, including EVERSANA, Lyfegen, Syneos Health, McKinsey & Company, ICON plc., Clarivate., Thermo Fisher Scientific Inc., Viseven, ZS Associates, Cloud Pharmaceuticals Inc., among others.

Artificial Intelligence in Precision Medicine Market

Artificial Intelligence in Precision Medicine Market Insight, Competitive Landscape, and Market Forecast – 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key AI in precision medicine companies, including TEMPUS, GE HealthCare, Qure.ai, Envisionit Deep AI (Pty) Ltd., Avicenna.AI, Aignostics, Inc., Proscia Inc., Ultivue, Inc., Prenosis, Inc., IBEX, Cleerly, Inc., Paige AI, Inc., Densitas® Inc., Photocure ASA, iCAD, Inc., Eko Health, Inc., Owkin, Inc, Massive Bio, Deep Bio Inc., Atomwise Inc., among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

CONTACT: Contact Us

Shruti Thakur 

info@delveinsight.com 

+14699457679

https://www.delveinsight.com/medical-devices

• Author
• Recent Posts

GlobeNewswire

GlobeNewswire,is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Latest posts by GlobeNewswire (see all)

• Vigil Neuroscience Enters into Definitive Merger Agreement to be Acquired by Sanofi - May 21, 2025
• U.S. Department of Commerce to Place Up to 721% Tariffs on Chinese Graphite - May 21, 2025
• Oyster Enterprises II Acquisition Corp Announces the Upsized Pricing of $220,000,000 Initial Public Offering - May 21, 2025